Teraflex Advance (glucosamine, chondroitin, ibuprofen) capsules №60 vial

Description

Teraflex Advance (glucosamine, chondroitin, ibuprofen) capsules №60 vial

Composition

active substances: glucosamine sulfate, sodium chondroitin sulfate, ibuprofen;

1 capsule contains 250 mg of glucosamine sulfate (as D-glucosamine potassium sulfate sulfate), 200 mg of sodium chondroitin sulfate, 100 mg of ibuprofen;

Excipients: PROSOLV SMCC® (microcrystalline cellulose, colloidal anhydrous silica), sodium starch glycolate (type A), crospovidone, povidone, silicon dioxide, pregelatinized starch, magnesium stearate, stearic acid, capsule shell dioxide (E 171).

Dosage form

Capsules.

Main physical and chemical properties: size 0 hard gelatin capsules, consisting of a blue cap and a white body with the inscription “THERAFLEX ADVANCE” and containing a powder from white to almost white with a faint odor.

Pharmacotherapeutic group

Anti-inflammatory / anti-rheumatic drugs in combination.
ATX code M01B.

Pharmacological properties

The drug stimulates the regeneration of cartilage tissue. In addition, it has an anti-inflammatory effect at the cellular level, stimulates the synthesis of endogenous proteoglycans and endogenous hyaluronic acid, reduces the catabolic activity of chondrocytes, by inhibiting the synthesis of certain enzymes that destroy cartilage tissue, such as estalase, collagenase, proteoglykinase and phospholipase-A2, N-acetylglycose and also inhibits the production of other substances that can damage cartilage (in vitro), such as superoxide radicals and lysosomal enzymes.

Indications

It is used for the treatment of pain syndrome arising in primary and secondary osteoarthritis of intervertebral discs and joints of the extremities.

Contraindications

The drug is not used if the patient has a history of information that he suffers from hypersensitivity to the ingredients of the drug, a tendency to gastrointestinal bleeding, gastric ulcer in the acute period, diseases of the optic nerve, phenylketonuria, hematopoietic disorders, cerebrovascular or other bleeding , diabetes mellitus and thrombophlebitis.
Due to the lack of data on the use of the drug in pediatric practice, Teraflex Advance is not prescribed for children under 18 years of age.

Application during pregnancy and lactation

Teraflex Advance capsules cannot be used to treat pregnant and lactating women.

Method of administration and dosage

To reduce the negative effects on the gastric mucosa and reduce the likelihood of side effects, capsules should be taken during or after meals. Adult patients receive the drug 2 capsules three times per knock.
The drug must not be taken in doses exceeding the maximum allowable. The maximum daily dose of Teraflex Advance is 12 capsules.
Duration of treatment in the prescribed dosage is 20 days. By the decision of the doctor, after the disappearance of acute pain, the patient can continue taking the drug in the dosage recommended by the doctor.
If, when taking the drug, the patient’s condition does not improve or the pain syndrome persists within 5 days from the start of taking the drug, it is necessary to consult a doctor about the advisability of further treatment.

Overdose

With prolonged use of the drug in high doses, the patient may develop disturbances in the functioning of the hematopoietic organs, and the patient may also experience dizziness, vomiting, nausea, headaches, psychomotor agitation, tremors, insomnia, disorientation in space, renal colic, papillary necrosis, increased sweating, heart rhythm disturbances, seizures,
To stabilize the condition, it is necessary to stop using the drug, after which the patient should rinse the stomach and prescribe the correct treatment. In case of severe overdose, the patient is prescribed forced diuresis, constant monitoring of the heart and bronchopulmonary system.

Side effects

Reception of Teraflex Advance capsules can be accompanied by the development of bronchospasm, nervous excitement, dyspeptic disorders, allergic reactions, bleeding from the upper gastrointestinal tract, ulcerative or erosive lesions of the digestive system, visual impairment, drowsiness, inflammation of the optic nerve, headache, angioedema.